Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer

Clinical trial NCT05163483 · UNKNOWN

Trial details

NCT number: NCT05163483
Sponsor: Ruihua Xu
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma

Start date: 2022-07-01
Primary completion: 2023-12-01
Enrollment: 87

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.